VIDEO: New immunotherapies developing for multiple myeloma

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Lots of new developments, I think. So one I mentioned, I guess we already have CAR T-cells and bispecific antibodies that are approved. There are now newer versions of these CAR T-cells, different ways of manufacturing, different targets that are being developed. For instance, things like allogeneic CAR T-cells off the shelf, CAR T-cells that target different proteins, CAR T-cells that target multiple proteins at the same time. And the same token, bispecific antibodies are also evolving, again, trispecific antibodies, again, antibodies that target more than one antigen at the same time. So immunotherapy is still a pretty large pipeline of things that are being developed.

Combination approaches, combining these new effective treatments with each other, combining them with other treatments is another area of focus for the pipeline, if you will, in the next five to seven years. And then non-immunotherapies for a class of drugs called cerebral modulating agents, targeted treatments for patients with certain genetic alterations. Those are also being developed. And so I would say the big focus in the coming years would be how to move these treatments safely to even earlier stages of treatment. How to combine these treatments with each other, and how to develop the next generation version of these treatments that are safer, more effective. And obviously then, moving not just to immunotherapies, but non-immune approaches that can augment the options for patients with multiple myeloma.